Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 2/20 | 0.48 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.42 |
| ▸ | GRM5 | P41594 | 4/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12870532 | 0.86 | PRMT5 (0.45) | PRMT5WDR77ITGB3ITGA2BGRM5 | |
| SCHEMBL24253347 | 0.83 | GRM5 (0.50) | PRMT5WDR77GRM5 | |
| SCHEMBL30162812 | 0.82 | PRMT5 (0.53) | PRMT5WDR77GRM5HRH3KCNH2 | |
| SCHEMBL24934195 | 0.82 | PRMT5 (0.53) | PRMT5WDR77GRM5HRH3KCNH2 | |
| SCHEMBL17660286 | 0.80 | HRH3 (0.43) | PRMT5WDR77GRM5HRH3KCNH2 | |
| SCHEMBL13622582 | 0.78 | PER2 (0.51) | PRMT5WDR77 | |
| SCHEMBL26711841 | 0.77 | PRMT5 (0.43) | PRMT5WDR77ITGB3ITGA2BGRM5 | |
| SCHEMBL29218274 | 0.74 | GRM5 (0.39) | PRMT5WDR77GRM5HRH3KCNH2 | |
| SCHEMBL30162918 | 0.74 | GRM5 (0.39) | PRMT5WDR77GRM5HRH3KCNH2 | |
| SCHEMBL12870511 | 0.73 | PRMT5 (0.38) | PRMT5WDR77ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034507-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034507-A1 | FARNESOID X RECEPTOR AGONISTS | NR1H4, NR1H3, NR1H2 | PRMT5 1781/4885WDR77 771/4885ITGB3 3127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.